Science ❯ Biotechnology ❯ Pharmaceuticals

Clinical Trials

Phase 3 Trials Product Development Immunotherapy mRNA Technology Drug Development Experimental Treatments Neuroreparative Therapies Veterinary Clinical Trials Cancer Treatments

3 ARTICLES

2mo ago

Apogee Secures $1.3 Billion Blackstone Package and Selects Mid‑Dose After Positive Phase 2

The company says the deal plus roughly $1.3 billion in cash should fund late‑stage development through potential approval with Blackstone taking tiered royalties on future sales.

3 ARTICLES

3mo ago

NervGen Prices $60 Million Public Offering of Shares and Warrants